InflaRx (IFRX) AI Stock Analysis

• Market Cap: $91.30M
• Dividend Yield: N/A
• Average Volume (3M): 790.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: 178.84%
• EPS Growth: -40.60%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.25
• Shares Outstanding: 67,133,270
• 10 Day Avg. Volume: 667,562
• 30 Day Avg. Volume: 790,725
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.02
• Enterprise Value/Revenue: -13.00
• Enterprise Value/Gross Profit: 0.42
• Enterprise Value/Ebitda: 0.05
• 1Y Price Target: $4.00
• Price Target Upside: 194.12% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 44 Neutral
• Price Target: $1.50 ▲(10.29% Upside)

InflaRx's overall stock score is primarily impacted by its poor financial performance, characterized by negative profitability and cash flow issues. Technical analysis provides some positive signals with short-term bullish momentum, but the long-term trend remains bearish. The valuation is also weak due to a negative P/E ratio and lack of dividend yield.

Positive Factors

Innovative Product Pipeline

InflaRx's focus on developing therapies for inflammatory diseases positions it well in the biopharmaceutical sector, offering potential for breakthrough treatments and partnerships.

Strategic Revenue Channels

InflaRx's diverse revenue streams through collaborations and partnerships provide financial stability and potential for growth, enhancing its ability to fund R&D.

Regained Nasdaq Compliance

Regaining Nasdaq compliance stabilizes InflaRx's market position, reducing delisting risks and reassuring investors about its operational and financial management.

Negative Factors

Negative Profitability

InflaRx's ongoing negative profitability and cash flow issues indicate challenges in achieving financial sustainability, which could impact its long-term viability.

Cash Flow Issues

Persistent cash flow challenges suggest InflaRx may struggle to fund operations and R&D without additional financing, potentially limiting its growth and innovation capacity.

Significant Losses

The significant losses highlight InflaRx's ongoing financial pressures, particularly in managing R&D costs, which could affect its ability to sustain and expand its product pipeline.

InflaRx Business Overview & Revenue Model

Company Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

How the Company Makes Money

InflaRx generates revenue primarily through the development and commercialization of its therapeutic candidates. The company may earn income through various channels, including grants, collaborations, and partnerships with larger pharmaceutical companies, which often provide funding in exchange for rights to market or co-develop its products. Additionally, successful clinical trials can lead to milestone payments from partners, while eventual product sales, if approved, will become a significant revenue stream. The company's strategic focus on addressing unmet medical needs in inflammatory diseases also increases its potential for attracting investment and partnerships, driving its earnings.

InflaRx Financial Statement Overview

Summary

InflaRx's financials reflect significant operational and financial challenges. The company is struggling with profitability and cash flow management, evident from negative margins and consistent cash outflows. While the balance sheet shows limited leverage, negative returns and persistent losses are concerning for future financial stability.

Income Statement

InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.

Balance Sheet

The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.

Cash Flow

InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	162.83K	165.79K	63.09K	0.00	0.00	0.00
Gross Profit	-4.99M	-3.15M	-469.17K	-585.85K	-696.14K	-664.03K
EBITDA	-44.73M	-45.55M	-42.06M	-31.29M	-46.90M	-32.47M
Net Income	-45.29M	-46.06M	-42.67M	-27.04M	-45.65M	-34.01M
Balance Sheet
Total Assets	73.44M	76.02M	120.21M	102.40M	125.14M	88.22M
Cash, Cash Equivalents and Short-Term Investments	48.00M	52.84M	90.27M	81.81M	83.41M	81.13M
Total Debt	599.11K	805.09K	1.12M	1.36M	1.43M	559.04K
Total Liabilities	16.40M	14.60M	17.63M	14.05M	19.86M	10.35M
Stockholders Equity	57.04M	61.42M	102.58M	88.35M	105.28M	77.86M
Cash Flow
Free Cash Flow	-43.17M	-48.60M	-37.89M	-33.91M	-39.97M	-36.62M
Operating Cash Flow	-43.12M	-48.56M	-37.81M	-33.74M	-39.94M	-36.53M
Investing Cash Flow	12.17M	52.36M	-17.70M	19.36M	-25.95M	21.36M
Financing Cash Flow	27.49M	386.45K	52.99M	1.94M	61.58M	9.17M

InflaRx Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Neutral. The current price of 1.36 is below the 20-day moving average (MA) of 1.42, above the 50-day MA of 1.09, and below the 200-day MA of 1.46, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 51.20 is Neutral, neither overbought nor oversold. The STOCH value of 52.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IFRX.

InflaRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	61 Neutral	106.46M	-2.13	-73.05%	―	-33.00%	54.91%
IFRX	44 Neutral	$91.30M	―	-62.38%	―	178.84%	-40.60%
CLSD	42 Neutral	20.94M	-0.68	88.41%	―	-44.63%	26.79%
CABA	39 Underperform	225.92M	-0.85	―	―	―	-41.69%
JSPR	35 Underperform	65.06M	-0.39	―	―	―	-17.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

InflaRx Corporate Events

InflaRx Regains Nasdaq Compliance with Share Price Recovery

On September 11, 2025, InflaRx N.V. announced it regained compliance with Nasdaq’s minimum bid price requirement after its share price met the $1.00 threshold for 10 consecutive business days. This development closes a compliance issue that began on July 11, 2025, when the company was notified of its non-compliance due to a prolonged period of low share prices. Regaining compliance is a positive step for InflaRx, potentially stabilizing its market position and reassuring stakeholders.

InflaRx Reports Significant Losses in H1 2025 Financials

InflaRx N.V. released its unaudited condensed consolidated financial statements for the six months ending June 30, 2025, reporting a significant loss. The company experienced a gross loss of €2.37 million and an operating loss of €25.92 million, despite generating €39,432 in revenue. The financial results highlight ongoing challenges in managing costs, particularly in research and development, which amounted to €14.22 million. The announcement underscores the financial pressures faced by InflaRx as it continues to invest heavily in its pipeline, impacting its market positioning and stakeholder confidence.

InflaRx Receives Nasdaq Deficiency Notice for Share Price

On July 11, 2025, InflaRx N.V. announced that it received a notice from Nasdaq indicating that its ordinary shares had closed below the minimum $1.00 per share requirement for the past 30 consecutive business days. The company has until January 7, 2026, to regain compliance, with a potential extension until July 6, 2026, if necessary. This notice does not immediately affect the listing or trading of InflaRx’s shares, and the company is exploring options to meet the compliance requirements.

InflaRx Appoints KPMG as New Auditor Following Shareholder Approval

On June 26, 2025, InflaRx N.V. announced a change in its independent registered public accounting firm, transitioning from EY GmbH & Co. KG to KPMG AG Wirtschaftsprüfungsgesellschaft for the fiscal year ending December 31, 2025. This decision, approved by shareholders during the Annual General Meeting on April 24, 2025, was not due to any disagreements with EY, whose reports had been unqualified and without adverse opinions.